What is Euclises Pharmaceuticals?
Euclises Pharmaceuticals is a specialized biopharmaceutical enterprise dedicated to the advancement of novel cyclooxygenase-2 (COX-2) inhibitors, branded as Euclicoxibs. By leveraging a strategic development partnership with the Guangzhou Institute of Biomedicine and Health (GIBH), the company has successfully identified ECP-1014 as its primary clinical development candidate. Headquartered within the BioGenerator Labs at CORTEX, the firm operates at the intersection of academic research and commercial drug development, focusing on high-impact oncology treatments. Its market position is defined by its commitment to precision medicine and the rigorous validation of its therapeutic candidates prior to human testing.
How much funding has Euclises Pharmaceuticals raised?
Euclises Pharmaceuticals has raised a total of $3.2M across 3 funding rounds:
Private Equity
$174K
Private Equity
$1.9M
Private Equity
$1.2M
Private Equity (2012): $174K with participation from St Louis Arch Angels
Private Equity (2013): $1.9M led by BioGenerator, Cultivation Capital, and St Louis Arch Angels
Private Equity (2015): $1.2M, investors not publicly disclosed
Key Investors in Euclises Pharmaceuticals
BioGenerator
Based in St. Louis, Missouri, BioGenerator creates and grows innovative companies through its two complementary approaches, investing through BioGenerator Ventures and comprehensive startup support through BioGenerator Labs.
Cultivation Capital
Cultivation Capital is a venture capital firm that invests in young companies with transformative ideas across various industries, including life sciences, software, agriculture, and geospatial technology.
St Louis Arch Angels
The St. Louis Arch Angels is a network of accredited investors dedicated to funding early-stage businesses in the St. Louis region, comprising experienced business leaders and scientists.
What's next for Euclises Pharmaceuticals?
With the recent influx of capital, Euclises Pharmaceuticals is poised to accelerate its transition into the clinical phase of drug development. The strategic focus will likely center on finalizing the regulatory and safety protocols required for human trials of ECP-1014. As the company moves forward, the emphasis will remain on maintaining its collaborative development model while scaling its operational capacity to meet the demands of late-stage research. Investors will be closely monitoring the firm's ability to hit key clinical milestones, which will serve as the primary catalyst for future valuation growth and potential exit opportunities in the biopharmaceutical sector.
See full Euclises Pharmaceuticals company page
